Cancer Diagnostics Market to reach us4 379 Billion by 2032; Breast Cancer to be key Area of Identification & Detection, reports FMI
Future Market Insights, Inc.
8 min read
In terms of market share and revenue, the North American market is predicted to be the most lucrative market for cancer diagnostics during the forecast period, 2022 and 2032. In 2021, the regional cancer diagnostics market boomed with a revenue share of 45%
NEWARK, DE / ACCESSWIRE / September 6, 2022 / During the forecast period 2022-2032, the cancer diagnostics market is expected to grow at a value of 7.1% CAGR, according to Future Market Insights. By the year 2032, the global market for cancer diagnostics is expected to rise up to a market valuation of US$ 379 Billion.
Cancer is one of the leading causes of death globally, and its prevalence is rising at an alarming rate. As a result, healthcare professionals are focusing on developing effective treatment and diagnosis options in order to minimize the incidence level. Early identification increases the likelihood of treatment regimen success. As a result, healthcare institutions and industrial firms are promoting routine checkups through various public awareness campaigns.
The increasing prevalence and incidence of various cancers, including lung cancer and breast cancer, will drive the cancer diagnostics market throughout the forecast period. Additionally, enhanced diagnostics laboratory infrastructure in developed countries is expected to fuel the market in the approaching years.
There will be a major increase in focus on health and safety rules throughout the forecast period, as well as a surge in adoption of yoga and other wellness practices. During the projection period, North America would dominate the worldwide cancer diagnostic market. The presence of many biotechnology and medical device enterprises is one of the key drivers fueling the diagnostics sector in the region.
North America is expected to continue its dominance over the projected period due to factors such as increasing R&D investment and broad adoption of new technologies. Furthermore, the region's high concentration of key companies, expanding FDA approvals, strategic collaborations, and significant investment in R&D activities are expected to boost the market.
Key Takeaways from the Market Study
In 2022, the global cancer diagnostics market is estimated to have a global market size of US$ 191 Billion.
By test type, the imaging segment gained a 58% market share in 2021.
By indication type, the breast cancer segment acquired a global market valuation of 34% in 2021.
The North American market for cancer diagnostics expanded with a market share of 45% in 2022.
The APAC cancer diagnostics market is expected to grow with a 6.9% CAGR during the forecast period.
The European region is projected to grow with a 5.2% CAGR during 2022-2032.
"Increasing oncologic case incidence, continual technical improvements in diagnostics, and rising need for efficient screening tests are some of the primary drivers driving global demand for diagnostic tools and procedures." comments a Future Market Insights analyst.
Competitive Landscape
The market is expected to become more competitive in the near future, as many companies focus their efforts on research and the creation of innovative diagnostic techniques through product line expansions, acquisitions, and mergers.
Bortezomib for Injection, a cancer therapy drug, was introduced in the United States in 2022 by Gland Pharma. According to the drug company, it has introduced the medicine in the US market through a partner who has obtained clearance from the US Food and Drug Administration (USFDA).
Bristol-Myers Squibb K.K. declared in 2022 that the Japanese Ministry of Health, Labour, and Welfare had accepted Abecma (idecabtagene vicleucel), a BCMA-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment for adult patients with refractory or relapsed (R/R) multiple myeloma who had received at least three prior therapies. Abecma was the first CAR T cell therapy approved in Japan in 2021 for the treatment of R/R multiple myeloma.
Future Market Insights, in its new offering, presents an unbiased analysis of the global cancer diagnostics market, presenting historical analysis from 2016 to 2021 and forecast statistics for the period of 2022-2032.
The study reveals essential insights on the basis of test type (tumor biomarkers tests, imaging, biopsy, liquid biopsy, immunohistochemistry, in situ hybridization), by indication (breast cancer, lung cancer, colorectal cancer, melanoma, blood cancer, prostate cancer, ovarian cancer, stomach cancer, liver cancer and others) and by end-user (hospital associated labs, independent, diagnostic laboratories, diagnostic imaging centers, cancer research institutes and others) and regions (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa).
About the Healthcare at Future Market Insights
The healthcare domain team at Future Market Insights offers expert analysis, time-efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis of key trends including competitive landscape, profit margin, and research development efforts.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centers in the UK, U.S., and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Brain Cancer Diagnostics Market - Brain Cancer Diagnostics Market - Global industry segment analysis, regional outlook, share, growth; brain cancer diagnostics market forecast 2016 to 2026 by future market insights
Cancer Tissue Diagnostics Market - Cancer Tissue Diagnostics Market is predicted to expand at over 8.5% CAGR through 2031. Cancer Tissue Diagnostics Market players relying on innovation to steer growth.
Early-Stage Lung Cancer Diagnostics Therapy Market - Early-Stage Lung Cancer Diagnostics Therapy Industry Analysis by Future Market Insights: Global Industry Segment Analysis, Demand, Covering Dominant Region, Early-Stage Lung Cancer Diagnostics Therapy Market Share, Growth, Competition Analysis, & Future prospects
Colorectal Cancer Molecular Diagnostics Market -The global colorectal cancer molecular diagnostics market garnered a market value of US$ 2.35 Billion in 2022 and is expected to accumulate a market value of US$ 5.07 Billion by registering a CAGR of 8% in the assessment period 2022-2032.
Cancer Antigens Market - Cancer Antigens Market - Global industry segment analysis, regional outlook, share, growth; Cancer Antigens 2019 to 2029 by Future Market Insights
About Future Market Insights, Inc.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
